Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

Table 2 MIC and cumulative percent inhibited distributions for plazomicin, in relation to the carbapenemase type produced by the 300 K. pneumoniae isolates

Carbapenemase	No of isolates	No of isolates / (cumulative % of isolates) inhibited at plazomicin MIC (mg/L) of ^a
Carbapenemase	No of isolates	≤0.125	0.25	0.5	1	2	4	8	16	32	≥64^b
KPC	200	3 (1.5)	46 (24.5)	46 (47.5)	57 (76.0)	18 (85.0)	11 (90.5)	3 (92.0)	0 (92.0)	0 (92.0)	16 (100)
NDM	50	1 (2.0)	23 (48.0)	13 (74.0)	11 (96.0)	2 (100)	0 (−)	0 (−)	0 (−)	0 (−)	0 (−)
VIM	21	3 (14.3)	3 (28.6)	3 (42.9)	5 (66.7)	1 (71.4)	0 (71.4)	0 (71.4)	0 (71.4)	0 (71.4)	6 (100)
OXA-48	12	1 (8.3)	2 (25.0)	5 (66.7)	2 (83.3)	1 (91.7)	1 (100)	0 (−)	0 (−)	0 (−)	0 (−)
KPC + VIM	14	0 (0.0)	2 (14.3)	0 (14.3)	8 (71.4)	3 (92.9)	1 (100)	0 (−)	0 (−)	0 (−)	0 (−)
NDM + OXA-48	2	0 (0.0)	2 (100)	0 (−)	0 (−)	0 (−)	0 (−)	0 (−)	0 (−)	0 (−)	0 (−)
KPC + OXA-48	1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (100)
All	300	8 (2.7)	78 (28.7)	67 (51.0)	83 (78.7)	25 (87.0)	13 (91.3)	3 (92.3)	0 (92.3)	0 (92.3)	23 (100)

^a The MIC inhibiting 90% of isolates (MIC₉₀) is bolded
^b All isolates (n = 23) with plazomicin MIC ≥64 mg/L harbored a 16S rRNA methylase gene

ISSN: 1471-2334